BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, December 9, 2024
Breaking News: Healing a health divide (that’s long overdue)
See today's BioWorld Science
Home
» PIV5-vectored OspA-based vaccine provides long-term protection against
B. burgdorferi
infection in mice
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Infection
PIV5-vectored OspA-based vaccine provides long-term protection against
B. burgdorferi
infection in mice
Feb. 21, 2024
No Comments
Immuno Technologies Inc. and affiliated organizations have published preclinical data on a novel parainfluenza virus 5 (PIV5)-vectored intranasal vaccine for Lyme disease.
BioWorld Science
Vaccines
Infection